Form 4: Forte Biosciences Director Acquires 31,000 Stock Options

Sentiment:

SEC Form 4 Filing


Director Scott C. Brun acquired 31,000 stock options in Forte Biosciences, Inc. on March 20, 2025.

Summary

  • On March 20, 2025, Scott C. Brun, a director of Forte Biosciences, Inc., acquired 31,000 stock options.
  • The options have an exercise price of $7.54.
  • The options vest in equal monthly installments over three years, contingent on continued service, and will be fully vested by March 20, 2028.
  • The expiration date for these options is March 20, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director. It suggests confidence but doesn't provide concrete financial data.

Positives

  • The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

  • The acquisition of stock options by a director may positively influence shareholder sentiment.

Key Dates

DateDescription
03/20/2025Date of earliest transaction: Scott C. Brun acquired 31,000 stock options.
03/20/2025Date of Grant for the stock options.
03/21/2025Date of signature by Attorney-in-Fact.
03/20/2035Expiration date of the stock options.

Keywords

Forte Biosciences, Stock Options, Director, Acquisition, Beneficial Ownership, Form 4, FBRX

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.